- Home
- ERAS vs TOI Comparison
ERAS vs TOI Comparison
Compare ERAS & TOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- TOI
- Stock Information
- Founded
- ERAS 2018
- TOI 2007
- Country
- ERAS United States
- TOI United States
- Employees
- ERAS N/A
- TOI N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- TOI Medical/Nursing Services
- Sector
- ERAS Health Care
- TOI Health Care
- Exchange
- ERAS Nasdaq
- TOI Nasdaq
- Market Cap
- ERAS 439.7M
- TOI 444.1M
- IPO Year
- ERAS 2021
- TOI N/A
- Fundamental
- Price
- ERAS $2.44
- TOI $4.68
- Analyst Decision
- ERAS Buy
- TOI Strong Buy
- Analyst Count
- ERAS 6
- TOI 2
- Target Price
- ERAS $3.67
- TOI $6.50
- AVG Volume (30 Days)
- ERAS 2.1M
- TOI 2.0M
- Earning Date
- ERAS 11-07-2025
- TOI 11-13-2025
- Dividend Yield
- ERAS N/A
- TOI N/A
- EPS Growth
- ERAS N/A
- TOI N/A
- EPS
- ERAS N/A
- TOI N/A
- Revenue
- ERAS N/A
- TOI $424,376,000.00
- Revenue This Year
- ERAS N/A
- TOI $21.71
- Revenue Next Year
- ERAS N/A
- TOI $20.58
- P/E Ratio
- ERAS N/A
- TOI N/A
- Revenue Growth
- ERAS N/A
- TOI 17.53
- 52 Week Low
- ERAS $1.01
- TOI $0.13
- 52 Week High
- ERAS $3.31
- TOI $4.88
- Technical
- Relative Strength Index (RSI)
- ERAS 59.41
- TOI 69.60
- Support Level
- ERAS $2.18
- TOI $4.44
- Resistance Level
- ERAS $2.65
- TOI $4.88
- Average True Range (ATR)
- ERAS 0.15
- TOI 0.31
- MACD
- ERAS -0.03
- TOI 0.07
- Stochastic Oscillator
- ERAS 55.79
- TOI 85.87
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About TOI The Oncology Institute Inc.
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.